>
For Clinicians

Evidence speaks best.

Every claim PANCREASaver® makes is backed by literature and regulatory approval — decision-ready information in 30 seconds.

TFDA Medical Device License: No. 007946

AUC 0.95

National multi-center validation: AUC 0.95

Scroll to watch the AUC curve draw — PANCREASaver® reaches 0.95 area under the curve detecting small <2cm tumors.

全國多中心驗證 ROC 曲線(AUC 0.95)— Radiology 220152 Figure 3

Figure source: Radiology 2023 (220152) Fig. 3 — nationwide multicenter validation (n=1,473) |Article ↗

92.1%
Sensitivity (<2cm tumors)
0.95
Multi-center AUC
2000+
Cases interpreted
10
Patents (TW & US)
Clinical Evidence

Every number, sourced

Five international publications, nine awards, approvals in two markets — PANCREASaver® speaks in verifiable evidence.

International publications

5 peer-reviewed papers in Lancet Digital Health, Radiology and other top journals — real clinical validation led by National Taiwan University Hospital.

View 5 papers

FDA Breakthrough Device

Breakthrough Device Designation from the U.S. FDA, recognizing technology that can significantly improve early detection of a life-threatening disease. FDA official program page ↗ Media coverage: NTUH breakthrough designation ↗

TFDA clearance (Taiwan)

Device license No. 007946 — the first licensed pancreatic cancer AI-assisted detection device in Taiwan.

Intellectual Property Portfolio

10 invention patents across Taiwan (6) and the US (4), written at both system and method level, covering algorithms, imaging and clinical workflow.

View 10 patents
Certifications & Awards

9 national recognitions

RSNA Margulis Award2023 · First for Taiwan
SNQ National Quality MarkHealthcare quality recognition
Taipei BioTech AwardInnovative technology
National Drug & Medical Device AwardGold award
National Innovation AwardInnovation recognition
FDA BreakthroughU.S. Breakthrough Device
Milestones

From fundamental research to clinical care

2016

Prof. Wang (NTU) and Prof. Liao (NTUH) launch early pancreatic cancer imaging AI research

2019

NTU research team begins multi-center clinical validation

2022.11

PanCAD.ai Co., Ltd. founded; technology licensed for commercialization

2023

First Margulis Award for Taiwan at RSNA; SNQ, Taipei BioTech, National Innovation Awards

2023

FDA Breakthrough designation; TFDA license No. 007946

2026

Deployed at medical centers, regional hospitals and health centers; 2,000+ cases

Key Publications

Every step, published

Lancet Digital Health

Multi-center validation of AI for early pancreatic cancer detection

Radiology

Deep learning for pancreatic lesion detection on CT

Other international journals

5 papers total, covering algorithms, clinical validation and workflow

Integration

Four weeks, contract to go-live

A dedicated project manager throughout; radiologist and technologist training included.

1

Week 1 · Assessment

Review equipment (CT model, PACS version) and workflow; define report format and alert rules.

2

Week 2 · Integration

AI server setup and PACS/RIS interfacing; automatic DICOM routing; zero extra steps for radiology.

3

Week 3 · Validation & training

Validation on institutional data plus training for radiologists and technologists (online course included).

4

Week 4 · Go-live

Go-live, pilot run, performance dashboard delivered. Monthly quality reports thereafter.

Want to know more? Let's talk.

Partnership, media, or careers — all welcome.

Contact Us